Gilead Sciences Inc.

Pharmaceuticals
United States
2016 Revenue (US$ Millions)$30,390
Revenue Growth (%)-6.89%
Net Income (US$ Millions)$13,501
Earnings Per Share (US$)$9.94
EPS Growth Rate (%)-16.54%
Profit Margin44.43%
Total Equity (US$ Millions)$18,887
Return on Equity (%)72.84%
Long Term Debt (US$ Millions)$26,346
Debt To Equity Ratio (%)1.39%
Total Assets (US$ Millions)$56,977
Current Assets (US$ Millions)$20,445
Current Liabilities (US$ Millions)$9,219
Cost of Goods Sold (US$ Millions)$4,261
Inventory Turnover2.41